SEARCH

SEARCH BY CITATION

References

  • 1
    Corry DB. Emerging immune targets for the therapy of allergic asthma. Nat Rev Drug Discov 2002;1:5564.
  • 2
    Cousins DJ, McDonald J, Lee TH. Therapeutic approaches for control of transcription factors in allergic disease. J Allergy Clin Immunol 2008;121:803809.
  • 3
    Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007;13:108116.
  • 4
    Cosmi L, Liotta F, Angeli R, Mazzinghi B, Santarlasci V, Manetti R et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25 +  regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004;103:31173121.
  • 5
    Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Ruckert B et al. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5:e329.
  • 6
    Thunberg S, Akdis M, Akdis CA, Gronneberg R, Malmstrom V, Trollmo C et al. Immune regulation by CD4+ CD25+  T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy 2007;37:11271136.
  • 7
    Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J et al. Relation of CD4+ CD25+  regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608615.
  • 8
    Grindebacke H, Wing K, Andersson AC, Suri-Payer E, Rak S, Rudin A. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004;34:13641372.
  • 9
    Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ et al. Quantitative and functional impairment of pulmonary CD4+ CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007;119:12581266.
  • 10
    Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994;7:324331.
  • 11
    Eklund A, Blaschke E. Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis. Thorax 1986;41:629634.
  • 12
    Velickovic TC, Thunberg S, Polovic N, Neimert-Andersson T, Gronlund H, Van Hage M et al. Low levels of endotoxin enhance allergen-stimulated proliferation and reduce the threshold for activation in human peripheral blood cells. Int Arch Allergy Immunol 2008;146:110.
  • 13
    Burgler S, Ouaked N, Bassin C, Basinski TM, Mantel PY, Siegmund K et al. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009;123:588595, 595 e1–7.
  • 14
    Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950957.
  • 15
    Morgan AJ, Symon FA, Berry MA, Pavord ID, Corrigan CJ, Wardlaw AJ. IL-4-expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR 3 and CCR 4. J Allergy Clin Immunol 2005;116:594600.
  • 16
    Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M et al. CD4+  invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 2006;354:11171129.
  • 17
    Vijayanand P, Seumois G, Pickard C, Powell RM, Angco G, Sammut D et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N Engl J Med 2007;356:14101422.
  • 18
    Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+ CD25- T cells. J Clin Invest 2003;112:14371443.
  • 19
    Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL et al. Analysis of FOXP3 protein expression in human CD4+ CD25+  regulatory T cells at the single-cell level. Eur J Immunol 2005;35:16811691.
  • 20
    Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345354.
  • 21
    Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4 + FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:29832990.
  • 22
    Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007;123:1829.
  • 23
    Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+  T reg cells. J Exp Med 2006;203:17011711.
  • 24
    Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:16931700.
  • 25
    Lee JH, Yu HH, Wang LC, Yang YH, Lin YT, Chiang BL. The levels of CD4+CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma. Clin Exp Immunol 2007;148:5363.
  • 26
    Ebner C, Schenk S, Najafian N, Siemann U, Steiner R, Fischer GW et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995;154:19321940.
  • 27
    Bullens DM, Van Den Keybus C, Dilissen E, Kasran A, Ceuppens JL. Allergen-specific T cells from birch-pollen-allergic patients and healthy controls differ in T helper 2 cytokine and in interleukin-10 production. Clin Exp Allergy 2004;34:879887.
  • 28
    Van Overtvelt L, Wambre E, Maillere B, Von Hofe E, Louise A, Balazuc AM et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol 2008;180:45144522.
  • 29
    Stassen M, Jonuleit H, Muller C, Klein M, Richter C, Bopp T et al. Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J Immunol 2004;173:267274.
  • 30
    Lin YL, Shieh CC, Wang JY. The functional insufficiency of human CD4 + CD25 high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation. Allergy 2008;63:6774.
  • 31
    Johansson MW, Kelly EA, Busse WW, Jarjour NN, Mosher DF. Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J Immunol 2008;180:76227635.
  • 32
    Teran LM, Carroll MP, Shute JK, Holgate ST. Interleukin 5 release into asthmatic airways 4 and 24 hours after endobronchial allergen challenge: its relationship with eosinophil recruitment. Cytokine 1999;11:518522.
  • 33
    Veldhoen M, Uyttenhove C, Van Snick J, Helmby H, Westendorf A, Buer J et al. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008;9:13411346.
  • 34
    Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008;9:13471355.
  • 35
    Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 2000;105(1 Pt 1):108115.
  • 36
    Erpenbeck VJ, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A et al. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol 2003;111:13191327.